{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:48:41Z","timestamp":1777502921967,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The cure or functional cure of the \u201cBerlin patient\u201d and \u201cLondon patient\u201d indicates that infusion of HIV-resistant cells could be a viable treatment strategy. Very recently, we genetically linked a short-peptide fusion inhibitor with a glycosylphosphatidylinositol (GPI) attachment signal, rendering modified cells fully resistant to HIV infection. In this study, GPI-anchored m36.4, a single-domain antibody (nanobody) targeting the coreceptor-binding site of gp120, was constructed with a lentiviral vector. We verified that m36.4 was efficiently expressed on the plasma membrane of transduced TZM-bl cells and targeted lipid raft sites without affecting the expression of HIV receptors (CD4, CCR5, and CXCR4). Significantly, TZM-bl cells expressing GPI-m36.4 were highly resistant to infection with divergent HIV-1 subtypes and potently blocked HIV-1 envelope-mediated cell-cell fusion and cell-cell viral transmission. Furthermore, we showed that GPI-m36.4-modified human CEMss-CCR5 cells were nonpermissive to both CCR5- and CXCR4-tropic HIV-1 isolates and displayed a strong survival advantage over unmodified cells. It was found that GPI-m36.4 could also impair HIV-1 Env processing and viral infectivity in transduced cells, underlying a multifaceted mechanism of antiviral action. In conclusion, our studies characterize m36.4 as a powerful nanobody that can generate HIV-resistant cells, offering a novel gene therapy approach that can be used alone or in combination.<\/jats:p>","DOI":"10.1038\/s41423-020-00627-y","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T13:05:50Z","timestamp":1610975150000},"page":"660-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy"],"prefix":"10.1038","volume":"18","author":[{"given":"Hongliang","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"627_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","volume":"26","author":"DA Collier","year":"2019","unstructured":"Collier, D. A., Monit, C. & Gupta, R. K. The impact of HIV-1 drug escape on the global treatment landscape. Cell Host Microbe 26, 48\u201360 (2019).","journal-title":"Cell Host Microbe"},{"key":"627_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nrmicro3132","volume":"11","author":"F Barre-Sinoussi","year":"2013","unstructured":"Barre-Sinoussi, F., Ross, A. L. & Delfraissy, J. F. Past, present and future: 30 years of HIV research. Nat. Rev. Microbiol. 11, 877\u2013883 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"627_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chom.2018.06.012","volume":"24","author":"G Alter","year":"2018","unstructured":"Alter, G. & Barouch, D. Immune correlate-guided HIV vaccine design. Cell Host Microbe 24, 25\u201333 (2018).","journal-title":"Cell Host Microbe"},{"key":"627_CR4","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S2352-3018(18)30095-X","volume":"5","author":"DH Barouch","year":"2018","unstructured":"Barouch, D. H. A step forward for HIV vaccines. Lancet HIV 5, e338\u2013e339 (2018).","journal-title":"Lancet HIV"},{"key":"627_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","volume":"38","author":"KE Stephenson","year":"2020","unstructured":"Stephenson, K. E., Wagh, K., Korber, B. & Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673\u2013703 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"627_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"627_CR7","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"627_CR8","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"627_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"627_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta, R. K. et al. HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation. Nature 568, 244\u2013248 (2019).","journal-title":"Nature"},{"key":"627_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter, G. et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692\u2013698 (2009).","journal-title":"N. Engl. J. Med."},{"key":"627_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/M14-1027","volume":"161","author":"TJ Henrich","year":"2014","unstructured":"Henrich, T. J. et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161, 319\u2013327 (2014).","journal-title":"Ann. Intern. Med."},{"key":"627_CR13","doi-asserted-by":"publisher","first-page":"e1002461","DOI":"10.1371\/journal.pmed.1002461","volume":"14","author":"NW Cummins","year":"2017","unstructured":"Cummins, N. W. et al. Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: a case study. PLoS Med. 14, e1002461 (2017).","journal-title":"PLoS Med."},{"key":"627_CR14","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu, L. et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 381, 1240\u20131247 (2019).","journal-title":"N. Engl. J. Med."},{"key":"627_CR15","doi-asserted-by":"publisher","first-page":"e1006956","DOI":"10.1371\/journal.ppat.1006956","volume":"14","author":"CW Peterson","year":"2018","unstructured":"Peterson, C. W. et al. Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: implications for HIV gene therapy. PLoS Pathog. 14, e1006956 (2018).","journal-title":"PLoS Pathog."},{"key":"627_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901\u2013910 (2014).","journal-title":"N. Engl. J. Med."},{"key":"627_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","volume":"70","author":"DM Eckert","year":"2001","unstructured":"Eckert, D. M. & Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777\u2013810 (2001).","journal-title":"Annu. Rev. Biochem."},{"key":"627_CR18","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175\u20132185 (2003).","journal-title":"N. Engl. J. Med."},{"key":"627_CR19","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","volume":"359","author":"RM Gulick","year":"2008","unstructured":"Gulick, R. M. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429\u20131441 (2008).","journal-title":"N. Engl. J. Med."},{"key":"627_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJMp1808729","volume":"379","author":"V Sheikh","year":"2018","unstructured":"Sheikh, V., Murray, J. S. & Sherwat, A. Ibalizumab in multidrug-resistant HIV\u2014accepting uncertainty. N. Engl. J. Med. 379, 605\u2013607 (2018).","journal-title":"N. Engl. J. Med."},{"key":"627_CR21","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.M800200200","volume":"283","author":"Y He","year":"2008","unstructured":"He, Y. et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283, 11126\u201311134 (2008).","journal-title":"J. Biol. Chem."},{"key":"627_CR22","doi-asserted-by":"publisher","first-page":"16332","DOI":"10.1073\/pnas.0807335105","volume":"105","author":"Y He","year":"2008","unstructured":"He, Y. et al. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl Acad. Sci. USA 105, 16332\u201316337 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR23","doi-asserted-by":"publisher","first-page":"e01839","DOI":"10.1128\/JVI.01839-16","volume":"91","author":"S Xiong","year":"2017","unstructured":"Xiong, S. et al. A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. J. Virol. 91, e01839\u201316. (2017).","journal-title":"J. Virol."},{"key":"627_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1097\/QAD.0000000000001073","volume":"30","author":"H Chong","year":"2016","unstructured":"Chong, H., Wu, X., Su, Y. & He, Y. Development of potent and long-acting HIV-1 fusion inhibitors. AIDS 30, 1187\u20131196 (2016).","journal-title":"AIDS"},{"key":"627_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/QAD.0000000000000498","volume":"29","author":"H Chong","year":"2015","unstructured":"Chong, H., Qiu, Z., Su, Y., Yang, L. & He, Y. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket. AIDS 29, 13\u201321 (2015).","journal-title":"AIDS"},{"key":"627_CR26","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1096\/fj.12-222547","volume":"27","author":"H Chong","year":"2013","unstructured":"Chong, H. et al. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. FASEB J. 27, 1203\u20131213 (2013).","journal-title":"FASEB J."},{"key":"627_CR27","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1074\/jbc.RA118.001729","volume":"293","author":"Y Zhu","year":"2018","unstructured":"Zhu, Y. et al. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. J. Biol. Chem. 293, 5323\u20135334 (2018).","journal-title":"J. Biol. Chem."},{"key":"627_CR28","doi-asserted-by":"publisher","first-page":"e01088","DOI":"10.1128\/JVI.01088-18","volume":"92","author":"H Chong","year":"2018","unstructured":"Chong, H., Zhu, Y., Yu, D. & He, Y. Structural and functional characterization of membrane fusion inhibitors with extremely potent activity against HIV-1, HIV-2, and Simian immunodeficiency virus. J. Virol. 92, e01088\u201318 (2018).","journal-title":"J. Virol."},{"key":"627_CR29","doi-asserted-by":"publisher","first-page":"e00775","DOI":"10.1128\/JVI.00775-18","volume":"92","author":"H Chong","year":"2018","unstructured":"Chong, H. et al. Design of novel HIV-1\/2 fusion inhibitors with high therapeutic efficacy in rhesus monkey models. J. Virol. 92, e00775\u201318 (2018).","journal-title":"J. Virol."},{"key":"627_CR30","doi-asserted-by":"publisher","first-page":"e00288","DOI":"10.1128\/JVI.00288-17","volume":"91","author":"H Chong","year":"2017","unstructured":"Chong, H. et al. A lipopeptide HIV-1\/2 fusion inhibitor with highly potent in vitro, ex vivo, and in vivo antiviral activity. J. Virol. 91, e00288\u201317 (2017).","journal-title":"J. Virol."},{"key":"627_CR31","doi-asserted-by":"publisher","first-page":"e02312","DOI":"10.1128\/JVI.02312-18","volume":"93","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. Design and characterization of cholesterylated peptide HIV-1\/2 fusion inhibitors with extremely potent and long-lasting antiviral activity. J. Virol. 93, e02312\u201318 (2019).","journal-title":"J. Virol."},{"key":"627_CR32","doi-asserted-by":"publisher","first-page":"e1007552","DOI":"10.1371\/journal.ppat.1007552","volume":"15","author":"H Chong","year":"2019","unstructured":"Chong, H. et al. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog. 15, e1007552 (2019).","journal-title":"PLoS Pathog."},{"key":"627_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.antiviral.2016.06.013","volume":"132","author":"Y Qiao","year":"2016","unstructured":"Qiao, Y. et al. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120. Antivir. Res. 132, 252\u2013261 (2016).","journal-title":"Antivir. Res."},{"key":"627_CR34","doi-asserted-by":"publisher","first-page":"63047","DOI":"10.18632\/oncotarget.18594","volume":"8","author":"Y Sun","year":"2017","unstructured":"Sun, Y., Qiao, Y., Zhu, Y., Chong, H. & He, Y. Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor. Oncotarget 8, 63047\u201363063 (2017).","journal-title":"Oncotarget"},{"key":"627_CR35","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1128\/JVI.02566-13","volume":"88","author":"W Chen","year":"2014","unstructured":"Chen, W. et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J. Virol. 88, 1125\u20131139 (2014).","journal-title":"J. Virol."},{"key":"627_CR36","doi-asserted-by":"publisher","first-page":"e66638","DOI":"10.1371\/journal.pone.0066638","volume":"8","author":"C Wan","year":"2013","unstructured":"Wan, C. et al. Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity. PloS one 8, e66638 (2013).","journal-title":"PloS one"},{"key":"627_CR37","doi-asserted-by":"publisher","first-page":"17121","DOI":"10.1073\/pnas.0805297105","volume":"105","author":"W Chen","year":"2008","unstructured":"Chen, W., Zhu, Z., Feng, Y. & Dimitrov, D. S. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc. Natl Acad. Sci. USA 105, 17121\u201317126 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR38","doi-asserted-by":"publisher","first-page":"e01177","DOI":"10.1128\/JVI.01177-19","volume":"93","author":"X Tang","year":"2019","unstructured":"Tang, X. et al. A membrane-anchored short-peptide fusion inhibitor fully protects target cells from infections of HIV-1, HIV-2, and Simian immunodeficiency virus. J. Virol. 93, e01177\u201319 (2019).","journal-title":"J. Virol."},{"key":"627_CR39","doi-asserted-by":"publisher","first-page":"e38126","DOI":"10.1371\/journal.pone.0038126","volume":"7","author":"Z Cao","year":"2012","unstructured":"Cao, Z. et al. The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus. PloS One 7, e38126 (2012).","journal-title":"PloS One"},{"key":"627_CR40","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/v2051146","volume":"2","author":"AA Waheed","year":"2010","unstructured":"Waheed, A. A. & Freed, E. O. The role of lipids in retrovirus replication. Viruses 2, 1146\u20131180 (2010).","journal-title":"Viruses"},{"key":"627_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.chom.2008.04.004","volume":"3","author":"K Leung","year":"2008","unstructured":"Leung, K. et al. HIV-1 assembly: viral glycoproteins segregate quantally to lipid rafts that associate individually with HIV-1 capsids and virions. Cell Host Microbe 3, 285\u2013292 (2008).","journal-title":"Cell Host Microbe"},{"key":"627_CR42","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.02853-13","volume":"88","author":"A deCamp","year":"2014","unstructured":"deCamp, A. et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88, 2489\u20132507 (2014).","journal-title":"J. Virol."},{"key":"627_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-79","volume":"7","author":"M Wen","year":"2010","unstructured":"Wen, M. et al. GPI-anchored single chain Fv\u2013an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology 7, 79 (2010).","journal-title":"Retrovirology"},{"key":"627_CR44","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1128\/JVI.01038-12","volume":"87","author":"L Liu","year":"2013","unstructured":"Liu, L. et al. Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J. Virol. 87, 1899\u20131905 (2013).","journal-title":"J. Virol."},{"key":"627_CR45","doi-asserted-by":"publisher","first-page":"e1002634","DOI":"10.1371\/journal.ppat.1002634","volume":"8","author":"IA Abela","year":"2012","unstructured":"Abela, I. A. et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 8, e1002634 (2012).","journal-title":"PLoS Pathog."},{"key":"627_CR46","doi-asserted-by":"publisher","first-page":"e1004966","DOI":"10.1371\/journal.ppat.1004966","volume":"11","author":"L Reh","year":"2015","unstructured":"Reh, L. et al. Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain- and epitope-dependent. PLoS Pathog. 11, e1004966 (2015).","journal-title":"PLoS Pathog."},{"key":"627_CR47","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.1128\/JVI.00783-15","volume":"89","author":"RB Gombos","year":"2015","unstructured":"Gombos, R. B. et al. Inhibitory effect of individual or combinations of broadly neutralizing antibodies and antiviral reagents against cell-free and cell-to-cell HIV-1 transmission. J. Virol. 89, 7813\u20137828 (2015).","journal-title":"J. Virol."},{"key":"627_CR48","doi-asserted-by":"publisher","first-page":"e02080","DOI":"10.1128\/JVI.02080-17","volume":"92","author":"A Misra","year":"2018","unstructured":"Misra, A. et al. Glycosyl-phosphatidylinositol-anchored anti-HIV Env single-chain variable fragments interfere with HIV-1 Env processing and viral infectivity. J. Virol. 92, e02080\u201317 (2018).","journal-title":"J. Virol."},{"key":"627_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"627_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18387-8","volume":"11","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat. Commun. 11, 4528 (2020).","journal-title":"Nat. Commun."},{"key":"627_CR51","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","volume":"27","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27, 846\u2013854 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"627_CR52","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu, L. et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 381, 1240\u20131247 (2019).","journal-title":"N. Engl. J. Med."},{"key":"627_CR53","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJMc1405805","volume":"371","author":"L Kordelas","year":"2014","unstructured":"Kordelas, L. et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 371, 880\u2013882 (2014).","journal-title":"N. Engl. J. Med."},{"key":"627_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20051970","volume":"203","author":"WG Glass","year":"2006","unstructured":"Glass, W. G. et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35\u201340 (2006).","journal-title":"J. Exp. Med."},{"key":"627_CR55","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1086\/524709","volume":"197","author":"E Kindberg","year":"2008","unstructured":"Kindberg, E. et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J. Infect. Dis. 197, 266\u2013269 (2008).","journal-title":"J. Infect. Dis."},{"key":"627_CR56","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1128\/JVI.00319-15","volume":"89","author":"T Hayashi","year":"2015","unstructured":"Hayashi, T., MacDonald, L. A. & Takimoto, T. Influenza A virus protein PA-X contributes to viral growth and suppression of the host antiviral and immune responses. J. Virol. 89, 6442\u20136452 (2015).","journal-title":"J. Virol."},{"key":"627_CR57","doi-asserted-by":"publisher","first-page":"10642","DOI":"10.1128\/JVI.01559-16","volume":"90","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. The glycosylphosphatidylinositol-anchored variable region of llama heavy chain-only antibody jm4 efficiently blocks both cell-free and T cell-T cell transmission of human immunodeficiency virus type 1. J. Virol. 90, 10642\u201310659 (2016).","journal-title":"J. Virol."},{"key":"627_CR58","doi-asserted-by":"publisher","first-page":"8467","DOI":"10.1128\/JVI.00520-11","volume":"85","author":"L Liu","year":"2011","unstructured":"Liu, L. et al. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J. Virol. 85, 8467\u20138476 (2011).","journal-title":"J. Virol."},{"key":"627_CR59","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11481-016-9681-x","volume":"11","author":"L Liu","year":"2016","unstructured":"Liu, L., Wen, M., Zhu, Q., Kimata, J. T. & Zhou, P. Glycosyl phosphatidylinositol-anchored C34 peptide derived from human immunodeficiency virus type 1 Gp41 Is a potent entry inhibitor. J. NeuroImmune Pharmacol. 11, 601\u2013610 (2016).","journal-title":"J. NeuroImmune Pharmacol."},{"key":"627_CR60","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1128\/JVI.00461-12","volume":"87","author":"J Matz","year":"2013","unstructured":"Matz, J. et al. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J. Virol. 87, 1137\u20131149 (2013).","journal-title":"J. Virol."},{"key":"627_CR61","doi-asserted-by":"publisher","first-page":"10173","DOI":"10.1128\/JVI.01332-13","volume":"87","author":"P Acharya","year":"2013","unstructured":"Acharya, P. et al. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. J. Virol. 87, 10173\u201310181 (2013).","journal-title":"J. Virol."},{"key":"627_CR62","doi-asserted-by":"publisher","first-page":"e01389","DOI":"10.1128\/JVI.01389-16","volume":"91","author":"C Ye","year":"2017","unstructured":"Ye, C. et al. Glycosylphosphatidylinositol-anchored anti-HIV scFv efficiently protects CD4 T cells from HIV-1 infection and deletion in hu-PBL mice. J. Virol. 91, e01389\u201316 (2017).","journal-title":"J. Virol."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-00627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-00627-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-00627-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T06:13:11Z","timestamp":1674886391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-00627-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["627"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-00627-y","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}